After being degraded by specific enzymes, the triple helical collagen molecule becomes thermally unstable and spontaneously unfolds at body temperature, leaving denatured collagen fragments covalently crosslinked within the partially degraded matrix.^[1,2]

Such denatured collagen is a hallmark indicator of inflammation and tissue damage under many pathological conditions, as well as programmed tissue remodeling during physiological and developmental events. 3Helix’s Collagen Hybridizing Peptide (CHP) is the first and only agent that specifically targets this biomarker in histopathology.^[1]

This powerful tool may enable straightforward applications in disease diagnosis, staging, as well as facile evaluation of therapeutic candidates by histology. CHP is applicable to nearly all tissue types and a wide range of medical areas, such as myocardial infarction, arthritis, nephritis, and fibrosis.